Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xinlu Ren

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Helicobacter|May 11, 2025
Reply: Is Tailored Bismuth Quadruple Therapy (With Clarithromycin or Furazolidone) Based on Fecal Molecular Susceptibility Testing in First-Line Helicobacter pylori Eradication Treatment More Effective? A Three-Arm, Multicenter Randomized Clinical TrialXinlu Ren, Zhiqiang Song
Cancer Biotherapy & Radiopharmaceuticals|August 9, 2020
The Regulatory Mechanisms of Dynamin-Related Protein 1 in Tumor Development and TherapyPeiyu Han, Xinlu Ren, Xiuxia Qu, et al.
Cell Biology International|August 27, 2020
Long non coding RNAs involved in MAPK pathway mechanism mediates diabetic neuropathic painXinlu Ren, Runan Yang, Lin Li, et al.
Oncology Letters|December 7, 2020
Abnormal expression of HNRNPA3 in multistep hepatocarcinogenesisXinlu Ren, Yi Dong, Miao Duan, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 16, 2023
Tailored triple plus bismuth therapy based on previous antibiotic medication history for first-line Helicobacter pylori eradication: A randomized trialZhiqiang Song, Baojun Suo, Xueli Tian, et al.
Helicobacter|October 21, 2025
Tailored Therapy Guided by Antibiotic Genotypic Resistances and CYP2C19 Polymorphisms Detected From Fecal Specimens for the First-Line Helicobacter pylori Eradication: A Randomized Controlled TrialBaojun Suo, Xinlu Ren, Cailing Li, et al.
Helicobacter|February 24, 2023
Individualized diagnosis and eradication therapy for Helicobacter pylori infection based on gene detection of clarithromycin resistance in stool specimens: A systematic review and meta-analysisXinlu Ren, Yanyan Shi, Baojun Suo, et al.
Chinese Medical Journal|April 3, 2023
Bismuth, esomeprazole, metronidazole, and minocycline or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trialBaojun Suo, Xueli Tian, Hua Zhang, et al.
Environmental Pollution (Barking, Essex : 1987)|January 18, 2026
Genome-Wide DNA Methylation Response of Paralichthys olivaceus to Ulva prolifera Decomposition Effluent StressYu Yang, Kunpeng Shi, Jie Ma, et al.
Helicobacter|February 8, 2023
New regimens as first-line eradication therapy for Helicobacter pylori infection in patients allergic to penicillin: A randomized controlled trialYuxin Zhang, Baojun Suo, Xueli Tian, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Helicobacter|May 11, 2025
Reply: Is Tailored Bismuth Quadruple Therapy (With Clarithromycin or Furazolidone) Based on Fecal Molecular Susceptibility Testing in First-Line Helicobacter pylori Eradication Treatment More Effective? A Three-Arm, Multicenter Randomized Clinical TrialXinlu Ren, Zhiqiang Song
Cancer Biotherapy & Radiopharmaceuticals|August 9, 2020
The Regulatory Mechanisms of Dynamin-Related Protein 1 in Tumor Development and TherapyPeiyu Han, Xinlu Ren, Xiuxia Qu, et al.
Cell Biology International|August 27, 2020
Long non coding RNAs involved in MAPK pathway mechanism mediates diabetic neuropathic painXinlu Ren, Runan Yang, Lin Li, et al.
Oncology Letters|December 7, 2020
Abnormal expression of HNRNPA3 in multistep hepatocarcinogenesisXinlu Ren, Yi Dong, Miao Duan, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 16, 2023
Tailored triple plus bismuth therapy based on previous antibiotic medication history for first-line Helicobacter pylori eradication: A randomized trialZhiqiang Song, Baojun Suo, Xueli Tian, et al.
Helicobacter|October 21, 2025
Tailored Therapy Guided by Antibiotic Genotypic Resistances and CYP2C19 Polymorphisms Detected From Fecal Specimens for the First-Line Helicobacter pylori Eradication: A Randomized Controlled TrialBaojun Suo, Xinlu Ren, Cailing Li, et al.
Helicobacter|February 24, 2023
Individualized diagnosis and eradication therapy for Helicobacter pylori infection based on gene detection of clarithromycin resistance in stool specimens: A systematic review and meta-analysisXinlu Ren, Yanyan Shi, Baojun Suo, et al.
Chinese Medical Journal|April 3, 2023
Bismuth, esomeprazole, metronidazole, and minocycline or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trialBaojun Suo, Xueli Tian, Hua Zhang, et al.
Environmental Pollution (Barking, Essex : 1987)|January 18, 2026
Genome-Wide DNA Methylation Response of Paralichthys olivaceus to Ulva prolifera Decomposition Effluent StressYu Yang, Kunpeng Shi, Jie Ma, et al.
Helicobacter|February 8, 2023
New regimens as first-line eradication therapy for Helicobacter pylori infection in patients allergic to penicillin: A randomized controlled trialYuxin Zhang, Baojun Suo, Xueli Tian, et al.
Pageof 2